HER-2/neu overexpression abrogates growth inhibitory pathways
US6767541B2 · kind B2 · utility
13Cited by
3References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 20, 2001 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | May 18, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.